PPARGC1A and metabolic dysfunction-associated steatotic liver disease: In a case-control study of NAFLD patients, hepatic DNA promoter methylation in PPARγ coactivator 1- α (PGC1-α), was significantly associated with differential liver DNA methylation in NAFLD and peripheral insulin resistance [85].